Kyowa Kirin Co.,Ltd. (4151) Cash flow
Market cap
¥1.26T
P/E ratio
16.7x
Kyowa Kirin manufactures and sells prescription pharmaceuticals through integrated operations from drug development to sales, serving healthcare markets globally.
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 23,885 | 23,126 | 23,029 | - | 16,243 | 18,797 | 20,466 | 19,498 | 18,476 | 21,096 | 24,780 | 26,144 |
| Cash from operations | 19,377 | 66,526 | 65,752 | 64,902 | 56,181 | 53,655 | 39,502 | 86,548 | 48,672 | 115,551 | 67,884 | 96,619 |
| Capital expenditures | -30,466 | -19,058 | -20,675 | - | -4,231 | -7,030 | -10,115 | -6,522 | -15,564 | -17,213 | -26,037 | -37,715 |
| Cash from investing | 16,805 | -57,747 | -48,968 | -45,265 | -39,929 | -933 | 252,559 | -11,363 | -17,185 | -20,382 | -142,387 | -89,189 |
| Payments for dividends | -13,683 | -13,682 | -13,680 | - | -16,148 | -21,688 | -23,631 | -24,176 | -25,258 | -29,027 | -30,895 | -30,882 |
| Repurchases of common stock | -116 | -232 | -8 | - | -14 | -22,601 | -14 | -23 | -11 | -10 | -40,014 | -9 |
| Cash from financing | -37,184 | -14,060 | -13,598 | -18,287 | -16,501 | -47,371 | -26,003 | -28,446 | -29,032 | -32,535 | -84,697 | -36,853 |
| Free cash flow | - | |||||||||||
| FCF margin (%) | - |